Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Factors for the Benefit of Stereotactic Body Radiotherapy for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience

NCT03604211 is registered in ClinicalTrials.gov with Kantonsspital Graubünden as lead sponsor.

NCT NCT03604211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03604211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Factors for the Benefit of Stereotactic Body Radiotherapy for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution Experience
Lead sponsor
Kantonsspital Graubünden
Phase
Observational
Overall status
Completed
Start date
January 31, 2010
Completion date
July 31, 2018
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymph node metastases, prostate cancer, prostate cancer recurrent